OncoMatch/Clinical Trials/NCT06251947
Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen
Is NCT06251947 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Efbemalenograstim Alfa for ovarian cancer.
Treatment: Efbemalenograstim Alfa — The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in Ovarian and Cervical cancer patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN).
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Cervical Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: bone marrow or stem cell transplantation
History of bone marrow or stem cell transplantation
Cannot have received: recombinant human granulocyte colony-stimulating factor
Treatment with recombinant human granulocyte colony-stimulating factor within 6 weeks prior to enrollment
Cannot have received: other investigational drugs
Use of other investigational drugs within 1 month prior to enrollment
Lab requirements
Blood counts
ANC ≥ 2.0 × 10^9/L, hemoglobin (Hb) ≥ 90.0 g/L, platelet (PLT) ≥ 80 × 10^9/L
Kidney function
creatinine clearance rate < 50 mL•min-1 (renal dysfunction is a risk factor for FN)
Liver function
bilirubin > 2.0 mg•dL-1 (hepatic dysfunction is a risk factor for FN); exclusion if acute infection, chronic active hepatitis B within 1 year (unless known negative for hepatitis B virus antigen prior to enrollment), or hepatitis C
Cardiac function
Left ventricular ejection fraction (LVEF) > 50%; exclusion if acute congestive heart failure, cardiomyopathy, or myocardial infarction
Before enrollment, neutrophil count (ANC) ≥ 2.0 × 10^9/L, hemoglobin (Hb) ≥ 90.0 g/L, and platelet (PLT) ≥ 80 × 10^9/L. LVEF > 50%. Hepatic dysfunction (bilirubin > 2.0 mg•dL-1) and renal dysfunction (creatinine clearance rate < 50 mL•min-1) are risk factors for FN. Exclusion if acute congestive heart failure, cardiomyopathy, or myocardial infarction.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify